Up and Coming

Up and Coming from Eisai and FogPharma

May 13, 2019

This is the first edition of a new feature highlighting changes in clinical research organizations’ personnel.

Bicycle Therapeutics
Two new executives were added to England-based Bicycle Therapeutics. Lisa Mahnke, formerly head of clinical development at Dragonfly Therapeutics and Syros Pharmaceuticals, will be head of clinical. Terrance West, formerly executive director of project management at EMD Serono, will be head of program management.

Attempting to bounce back after the clinical failure of aducanumab, Eisai Pharmaceuticals has brought new blood to its Alzheimer’s disease clinical development programs. Michael Irizarry, formerly of the company’s epilepsy group, will head up the effort, and former Sorbonne University professor Harald Hampel will guide the group’s global medical strategies.

Boston-based FogPharma has named Howard Stern as its chief scientific officer. Prior to joining FogPharma, Stern was vice president of translational sciences at Juno Therapeutics, managing teams responsible for correlative studies and pharmacology of CAR-T cell candidates.

Mohammed Dar has been named head of clinical development and chief medical officer at Immunocore Limited, responsible for clinical, operational, biostatistics and medical affairs functions across all therapeutic areas, including the company’s lead program, tebentafusp. Dar was most previously head of clinical development oncology, R&D at MedImmune (AstraZeneca).

Kyn Therapeutics
Jeffrey Ecsedy has been named CSO and Jason Sager named CMO of Boston-based Kyn Therapeutics. Ecsedy was formerly a member of the Oncology R&D leadership team at Takeda Pharmaceuticals as head of oncology translational medicine. Sager previously served as a senior medical director in Sanofi’s oncology division, leading the development of an early-stage clinical portfolio.